Global Rheumatoid Arthritis Market CAGR 5.5% by 2032 | Increasing Emphasis on Reducing Diagnostic Delays to Stimulate Market Growth

The global rheumatoid arthritis market size is expected to be US$ 799.9 million in 2025, reaching US$ 1,163.6 million by 2032, and exhibiting a CAGR of 5.5% during the forecast period of 2025-2032. Deepening research on microbiome-modulating therapies targeting systemic inflammation in rheumatoid arthritis (RA) and the initiation of early-stage trials of such therapies by biotech firms are rapidly expanding the scope of this market.

Recent Market Trends

• Oral Janus kinase (JAK) inhibitors such as upadacitinib (Rinvoq) and filgotinib are becoming increasingly commonplace in the rheumatoid arthritis (RA) treatment landscape, offering alternatives to injectable biologics with faster onset and convenient administration.
• Research institutions such as the Mayo Clinic and IBM Research are advancing AI algorithms capable of identifying rheumatoid arthritis at preclinical stages using synovial imaging and genetic markers.
• Biosimilar versions of widely adopted biologics such as adalimumab (Humira) are increasingly gaining ground across Germany, India, and South Korea, offering cost savings of nearly 40% and driving market democratization.
• Companies such as Biogen are piloting smart wearables integrated with machine learning to track flare-ups and joint stiffness in RA patients remotely.

• July 2025: AbbVie initiated a Phase 2 clinical study to assess the efficacy and safety of new targeted therapies for rheumatoid arthritis. The trial tests three treatment approaches in the form of Lutikizumab alone, Ravagalimab alone, and a combination of both against placebos. This study aims to provide better options for RA patients who have not responded well to existing treatments. The announcement highlights AbbVie's ongoing commitment to advancing RA therapies and may positively impact its stock performance.
• June 2025: Pfizer announced that its XELJANZ XR (tofacitinib) showed positive results in Phase 3b/4 studies for treating moderately to severely active rheumatoid arthritis, particularly in patients achieving low disease activity. The ORAL Shift study demonstrated that patients could taper off methotrexate while maintaining RA control on XELJANZ XR. Clinical trials have shown that XELJANZ improves symptoms and physical function with response rates significantly higher than placebo, and benefits were observed as early as 2 weeks into treatment. Common side effects include infections and headache.
• April 2025: Sandoz filed an antitrust lawsuit in the United States against Amgen, accusing it of unlawfully using a "thicket of patents" to maintain its monopoly on the arthritis drug Enbrel (etanercept) through 2029. This practice allegedly blocks more affordable biosimilar competition, including Sandoz's FDA-approved biosimilar Erelzi (etanercept-szzs), which has been approved since 2016 but not yet launched in the U.S. Sandoz claims that Amgen's actions have prevented around 7.5 million Americans with chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, from accessing lower-cost treatment options.

Segmental Analysis

In the diagnostics segment, serology tests remain the mainstay diagnostic solution, expected to capture the largest market share in 2025 due to their high specificity, affordability, and clinical utility in early autoimmune detection. Widely adopted assays such as rheumatoid factor (RF) and anti-CCP antibody tests are routinely embedded in diagnostic protocols across primary and specialist care, enabling faster diagnosis and improved treatment planning. On the treatment side, hospitals lead the end-user landscape, underpinned by their integrated infrastructure for administering biologics such as TNF inhibitors and JAK inhibitors. These facilities also have assured access to advanced imaging, lab diagnostics, and surgical interventions for complex cases. Strong reimbursement frameworks and multidisciplinary care models have positioned hospitals as the central hubs for chronic autoimmune care.

Regional Analysis

The rheumatoid arthritis market share is anticipated to be dominated by North America in 2025, particularly the U.S., where the focus of the healthcare sector is shifting toward personalized, integrated care models, blending diagnostics, biologic drug delivery, patient education, and tele-rheumatology platforms. With approximately 1.3 million adults across the United States afflicted with RA, according to a study published by the National Institutes of Health (NIH), there is a noticeable increase in the uptake of biosimilar and home-based infusion therapies. These changing preferences are further supported by favorable reimbursement mechanisms for digital monitoring and chronic disease management.

Across Europe, Germany, France, and the U.K. are advancing decentralized care through outpatient specialty clinics and virtual rheumatology consultations. Scandinavian countries are leading with national screening programs and early diagnosis campaigns, aligning with the value-based care initiatives implemented across the European Union (EU). In Asia Pacific, on the other hand, accelerated growth of the rheumatoid arthritis market is envisaged owing to improving healthcare infrastructure, expanding access to specialty clinics and advanced diagnostics in urban zones, and government-led health initiatives in India, China, and Southeast Asia.

Industry Players

The cornucopia of opportunities present in the global rheumatoid arthritis market has turned it into an intensely competitive arena, as hospitals, private rheumatology centers, and telehealth platforms are racing to deliver more personalized, outcomes-focused care.

Major industry players such as Novartis, Pfizer, AbbVie, and Bristol-Myers Squibb are aggressively conducting clinical trials to speed up regulatory approvals and release their drugs into the market to gain an early advantage.

On the other hand, large healthcare networks are integrating biologic therapy administration, long-term disease monitoring, and diagnostics into unified care pathways, utilizing digital platforms to improve and enhance patient outcomes. Private specialty clinics are taking wholesome efforts to offer faster access to infusion therapies and personalized protocols outside hospital-based systems. At the same time, tele-rheumatology is gathering momentum in rural and underserved regions, showing promising prospects for scalable follow-up care and remote consultations.